摘要
目的:探究Th17细胞在痤疮发生过程中的作用机理及与痤疮严重度的相关性。方法:根据Pillsbury法将136例对象分成对照组、轻度痤疮组、中度痤疮组和重度痤疮组。然后利用流式细胞仪检测Th17细胞在各组间的表达量;采用ELISA方法检测血清中IL-17、IL-23、IL-6、转化生长因子(TGF)-β1的表达水平,最后通过RT-PCR方法分别测定孤独核受体γt(RORγt)mRNA和IL-17 mRNA表达水平。结果:实验结果表明,中重度痤疮患者血清中IL-17、IL-23的表达量明显高于对照组和轻度痤疮患者(P<0.05),中重度痤疮组的IL-6、TGF-β1的表达量与对照组相比差异有统计学意义(P<0.05),中度痤疮组IL-6、TGF-β1的表达量与轻度痤疮患者差异无统计学意义(P>0.05);此外,IL-17 mRNA和RORγt mRNA的表达在各组间均存在统计学差异(P<0.05)。结论:Th17细胞在轻度痤疮、中度痤疮和重度痤疮中有级联放大作用,这可为今后重度痤疮探索治疗提供新靶点。
AIM： To investigate the mechanism of Th17 cells in acne development and its correlation with severity. METHODS： One hundred and thirty six cases were divided into control,mild,moderate and severe acne group according to the Pillsbury method. The expression levels of IL-17,IL-23,IL-6 and TGF-β1 in serum were detected by ELISA.RORγt mRNA and IL-17 mRNA expression levels were detected by RT-PCR. RESULTS： The levels of IL-17 and IL-23 in serum of patients with moderate to severe acne were significantly higher than those of the control and mild acne groups（ P〈0. 05）. The levels of IL-6 and TGF-β1 in moderate and severe acne groups were significantly higher than those of control group（ P〈0. 05）. There was no significant difference in the expression of IL-6 and TGF-β1 between mild and moderate acne groups（ P〈0. 05）.In addition,the expressions of IL-17 mRNA and RORγt mRNA from mild to severe groups were significantly different from control group（ P〈0. 05）.And there was significant difference between the three groups（ P〈0. 05）. CONCLUSION： Th17 cells have a cascade effect in mild,moderate and severe acne groups,which can provide a new target for future treatment of severe acne.
作者
陆威
周炳荣
汤怡
樊一斌
陶小华
LU Wei;ZHOU Bingrong;TANG Yi;FAN Yibin;TAO Xiaohua(Department of Dermatology, Zhefiang Provincial People ＂s Hospital, Hangzhou 310014, Zhejiang , China;Department of Dermatology, People ＂s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang, China;Department of Dermatology, the First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, Jiangsu, China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2018年第1期83-87,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
浙江省医药卫生科技项目(2015KYA020)
